Cardiogenic shock (CS) is a complex multifactorial clinical syndrome with extremely high
mortality, developing as a continuum, and progressing from the initial insult (underlying …

For many years, bleeding has been perceived as an unavoidable consequence of strategies
aimed at reducing thrombotic complications in patients undergoing percutaneous coronary …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Most patients with atrial fibrillation (AF) and risk factors for stroke require oral anticoagulation
(OAC) to decrease the risk of stroke or systemic embolism. This is now best achieved with …

A growing number of patients undergoing percutaneous coronary intervention (PCI) with
stent implantation also have atrial fibrillation. This poses challenges for their optimal …

Background: The platelet inhibitory effects induced by oral P2Y12 receptor antagonists are
delayed in patients with ST-segment–elevation myocardial infarction undergoing primary …

Cangrelor is the only currently available intravenous platelet P2Y12 receptor inhibitor. It is
characterized by potent, predictable, and rapidly reversible antiplatelet effects. Cangrelor …

Background Contemporary practices for hemodynamically supported high-risk
percutaneous coronary intervention have evolved over the last decade. This study sought to …

The contribution of natural products (NPs) to cardiovascular medicine has been extensively
documented, and many have been used for centuries. Cardiovascular disease (CVD) is the …

Oral antiplatelet drugs are crucially important for patients with acute coronary syndrome or
stable coronary artery disease undergoing percutaneous coronary intervention (PCI). In …